title: Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
abstract: OBJECTIVE
  Patient perception of overactive bladder (OAB) treatment outcomes can be a useful indicator of benefit and may help drive persistence on treatment, which is known to be poor in OAB. It remains unclear whether OAB patients dissatisfied with one antimuscarinic can achieve satisfaction with another and supporting data are limited. This study investigated patient-reported outcomes and clinical parameters during darifenacin treatment in OAB patients who expressed dissatisfaction with prior extended-release (ER) oxybutynin or tolterodine therapy (administered for >or= 1 week within the past year).
  
  
  METHODS
  This open-label study was conducted in darifenacin-naïve OAB patients. Patients received 7.5 mg darifenacin once daily with the possibility of up-titrating to 15 mg after 2 weeks, for up to 12 weeks. Efficacy parameters included the Patient's Perception of Bladder Condition (PPBC), patient satisfaction with treatment, micturition frequency and number of urgency and urge urinary incontinence (UUI) episodes. Adverse events (AEs) were also recorded.
  
  
  RESULTS
  In total, 497 patients were treated (84.1% women). Darifenacin treatment resulted in statistically significant improvements in PPBC scores, micturition frequency, urgency and UUI episodes from baseline at 12 weeks. The improvements were similar for patients previously treated with oxybutynin ER or tolterodine ER. More than 85% of patients expressed satisfaction with darifenacin. As noted in other studies, the most common AEs were dry mouth and constipation, but these infrequently resulted in treatment discontinuation, which was low overall.
  
  
  CONCLUSIONS
  In this study, PPBC score and OAB symptoms were significantly improved, and satisfaction was high during treatment with darifenacin (7.5/15 mg) in patients who were dissatisfied with the previous antimuscarinic treatment.
authors.affiliation: Western Clinical Research, Inc., Torrance, CA 90505, USA. wewedoc@aol.com
authors.forename: N
authors.initials: N
authors.lastname: Zinner
authors.forename: K C
authors.initials: KC
authors.lastname: Kobashi
authors.forename: U
authors.initials: U
authors.lastname: Ebinger
authors.forename: A
authors.initials: A
authors.lastname: Viegas
authors.forename: M
authors.initials: M
authors.lastname: Egermark
authors.forename: E
authors.initials: E
authors.lastname: Quebe-Fehling
authors.forename: P
authors.initials: P
authors.lastname: Koochaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001572:Benzofurans / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011759:Pyrrolidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D014554:Urination / Q000502:physiology; D055815:Young Adult
chemical_list: D001572:Benzofurans; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; C101207:darifenacin